Table 1: Proposed Standards for Reporting Long-term Outcomes after VT Ablation For Clinical Trials.

Required Follow-up Duration

• VT recurrence* (minimum follow-up duration of 6–12 months)

• Mortality (minimum follow-up duration of 1 year)

Efficacy Endpoints

• Spontaneous recurrence of any sustained VT

• Freedom from VT in absence of antiarrhythmic drug use (follow-up begins 5 half-lives after drug discontinuation, or 3 months after stopping amiodarone)

• Death

Other Outcomes that should be Reported if Possible

• Number of VT recurrences during follow-up period

• Recurrence of monomorphic VT (as opposed to VF or polymorphic VT)

• Freedom from VT with previously ineffective antiarrhythmic therapy

• Improvement in VT frequency (i.e. >75 % decrease in VT frequency for 6-month monitoring period before and after ablation)

• Quality of life

• Cost-effectiveness

*Ventricular tachycardia (VT) recurrence = any VT episode lasting >30 s or requiring implantable cardioverter-defibrillator intervention.